Abstract
To discuss the activities and roles of a bioventure company through the experiences at NanoCarrier Co., Ltd., whose core technology, micellar nanoparticle technology, was proposed and has been researched by Professor Kazunori Kataoka of University of Tokyo and Professor Teruo Okano of Tokyo Women's Medical University, and which was established for developing and commercializing DDS drug products for the treatment of cancer utilizing its technology.